Suchergebnisse - (Subject:"Siltuximab")

PubPharm (42)

1

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

enthalten in: Blood advances | 2022

von van Rhee, F. | Rosenthal, A. | Kanhai, K. | +4

2

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID) : a factorial, randomised, controlled trial

enthalten in: The Lancet. Respiratory medicine | 2021

von Declercq, J. | Van Damme, K. | De Leeuw, E. | +40

CommentIn: Lancet Respir Med. 2021 Dec;9(12):1353-1354. - PMID 34756179

3

Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19

enthalten in: Leukemia | 2021

von Gritti, G. | Raimondi, F. | Bottazzi, B. | +19

ErratumIn: Leukemia. 2021 Jun 28;:. - PMID 34183767

4

Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19

enthalten in: Thorax | 2021

von Khan, F. | Stewart, I. | Fabbri, L. | +4

5

Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome

enthalten in: Cell reports. Medicine | 2021

von Chen, L. | Biggs, C. | Jamal, S. | +3

6

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease

enthalten in: The Korean journal of internal medicine | 2021

von Min, G. | Jeon, Y. | Park, S. | +14

7

Interleukin-6 blocking agents for treating COVID-19 : a living systematic review

enthalten in: The Cochrane database of systematic reviews | 2021

von Ghosn, L. | Chaimani, A. | Evrenoglou, T. | +21

CommentIn: Ann Intern Med. 2021 Jun;174(6):JC63. - PMID 34058104

8

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab

enthalten in: British journal of haematology | 2021

von van Rhee, F. | Rossi, J. | Simpson, D. | +10

9

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2019

von Brighton, T. | Khot, A. | Harrison, S. | +15

10

Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease : secondary analyses of phase II clinical trial data

enthalten in: British journal of haematology | 2019

von Morra, D. | Pierson, S. | Shilling, D. | +6

1
2
3
4
5
Nächster »
[5]